CINV


Also found in: Acronyms.

chemotherapy-induced emesis

An adverse effect of many chemotherapeutics, which is usually self-limited and rarely life-threatening.
 
Highly emetogenic
Cisplatin, carmustine, dacarbazine, dactinomycin, mechlorethamine (nitrogen mustard), streptozocin.
 
Moderately emetogenic
Azacitidine, arparginase, carboplatin, cyclophosphamide, doxorubicin, mitomycin.
 
Management
Dopamine (D2 high-dose metoclopramide), serotonin (5-HT3 receptor antagonists—e.g., ondansetron),
References in periodicals archive ?
Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK1 RA to significantly reduce CINV in both the acute phase (0 - 24 hours after chemotherapy) and the delayed phase (24 - 120 hours after chemotherapy).
Drugs containing synthetic THC (dronabinol, nabilone) have been approved for use in the United States for CINV, and an oil containing CBD (Epidiolex) has shown promise in controlled trials for managing intractable epilepsy in children.
In a small (N = 64) parallel-group RCT, Meiri et al (27) compared dronabinol with the commonly used antiemetic ondansetron and with a combination of dronabinol and ondansetron for treating CINV in adults.
Finding affordable healthcare solutions that are effective and reduce or delay CINV in patients undergoing chemotherapy may make a significant impact on health outcomes and quality of life.
Since NK1 receptor antagonists are used in combination with 5-HT3 receptor antagonists, CINVANTI offers a strong strategic and operational fit with Heron's existing commercial product, SUSTOL[R], our extended-release, injectable product that incorporates the 5-HT3 receptor antagonist granisetron and is also indicated for the prevention of CINV.
CINV occurs in 70-80% patients treated with chemotherapy [2, 3].
The side effects of aprepitant therapy have been monitored in clinical trials in patients using aprepitant for depression and prevention of CINV and PONV.
CINV, Instituto de Neurociencia, Facultad de Ciencias, Universidad de Valparaiso
Chemotherapy-Induced Nausea and Vomiting (CINV) are two of the major factors which contribute to fear, anxiety and apprehension in patients with cancer.
Under the new arrangement, Helsinn Therapeutics Inc., the US affiliate of Helsinn, will obtain exclusive rights to promote and sell Akynzeo (netupitant/palonosetron), its oral fixed dose combination product for the prevention of CINV. Akynzeo had previously been co-promoted in the US by both Helsinn and Eisai.
In 1985, the FDA approved dronabinol for the treatment of chemotherapy-induced nausea and vomiting (CINV) not controlled by other medications.
Since the utilization of liposomal doxorubicin reduces the severity of chemotherapy-induced nausea and vomiting (CINV) in conjunction with the treatment of nonliposomal conventional doxorubicin, it is deemed to reduce the direct cost related to the CINV.